Unacon has six business segments, including more than 30 subsidiaries such as Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ou Yi Pharmaceutical, Enbipu Pharmaceutical and Yinhu Pharmaceutical, which are located in Hebei, Tianjin, Kyrgyzstan, Shaanxi, Liaoning, Shandong, Inner Mongolia and Hong Kong. Among them, China Pharmaceutical Group Co., Ltd., a holding subsidiary of Hong Kong, is the first overseas listed company in China pharmaceutical industry and one of the largest listed pharmaceutical companies in Hong Kong at present. At the same time, it is also one of the constituent stocks of Hong Kong Hang Seng Red Chip Index, and it has been rated as one of the 65,438+000 outstanding listed companies in Asia with a turnover of less than US$ 65,438 billion by the world-famous Forbes magazine twice in a row.
Unocon is mainly engaged in research and development, production and sales of pharmaceutical products. Products mainly include antibiotics, vitamins, cardiovascular and cerebrovascular diseases, antipyretic and analgesic drugs, digestive system drugs, respiratory system drugs, Chinese patent medicines and other seven series of nearly 1,000 varieties. At present, the annual production capacity of 8 products such as vitamin C, penicillin, amoxicillin, caffeine and 7-ACA ranks first in the world. The annual production capacity of Younuokang preparation is 3 billion injections, 20 billion tablets, 8 billion capsules and 654.38+0 billion soft capsules. The output, scale and strength of Unocal's leading products are among the best in China, and it has developed into one of the largest production bases of chemical raw materials and comprehensive preparations in China. At present, Unacon has 30 products with sales exceeding 100 million yuan, and the products are sold all over the country and more than 60 countries and regions around the world.
Since its establishment 10 years ago, with the strong support from all walks of life, Unakang has been constantly innovating and enterprising, achieving sustained, healthy and rapid development and achieved gratifying results. The comprehensive strength of the enterprise has always been in the forefront of the pharmaceutical industry in China, and it has successively won the honorary titles of National Advanced Collective of Pharmaceutical System, Advanced Enterprise of Quality and Benefit, Product Quality Assured Commitment Unit, National May 1 Labor Award, and China Environmental Protection Enterprise Love Award. In 20 10, the sales revenue of the whole group reached1308.8 billion, up 23% year-on-year, ranking second in the national pharmaceutical industry for three consecutive years; Profits and taxes reached 65.438+60.5 billion yuan, a year-on-year increase of 654.38+00.22%; Pay various taxes of 730 million yuan; Export earned 550 million US dollars, a year-on-year increase of 22%, and the total export volume continued to rank first in the domestic pharmaceutical industry.
In terms of research and development, Younuokang has successively developed more than one national new drug 1 10 in recent years, relying on the enterprise's "postdoctoral research center", the national enterprise technology center, the "863 Program" high-tech industrialization base and the Hebei Medical Engineering Technology Center, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields. At present, Unacon * * * has applied for more than 220 patents, including 1 16, applied for PCT international patent 17, and authorized 18 countries. Among them, the national first-class new drug "Enbipu" with independent intellectual property rights is the world's leading drug in the field of stroke treatment, and it is the third national first-class new drug with independent intellectual property rights in China, and it has obtained patent protection in 86 countries around the world. At present, the company has signed an agreement with two well-known companies in the United States and South Korea on the transfer of the patent right of Enbip soft capsules in Europe, America and South Korea, which has created a precedent for China pharmaceutical enterprises to transfer medical intellectual property rights to the most developed countries in the world and won honor for the country and the nation. In 2008, under the leadership of the Ministry of Science and Technology and with the support of the National Science and Technology Support Program, China Antibiotic Industry Technology Innovation Alliance was established. In the national special declaration of "Major New Drug Creation", 1 innovative drug incubation base, 3 innovative drug R&D technology platforms and 6 new drug R&D projects have settled in Shi Yao. In 2009, the group's pharmaceutical preparation and drug release technology laboratory ranked among the "National Key Laboratories", and the project "Butylphthalide Raw Materials and Soft Capsules" won the second prize of national scientific and technological progress, and the group was jointly rated as "National Innovative Enterprise" by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council and the All-China Federation of Trade Unions, which indicated that the group's innovation system entered a new stage of systematization and institutionalization.
In terms of product quality, Unocal has established a complete three-level quality management system, all drugs have passed GMP certification, and all subordinate enterprises have passed ISO9000, OHSAS 18000, ISO 1400 1 certification, and the product market inspection qualification rate has always remained at 100%. At the same time, enterprises improve the quality connotation with technology. At present, caffeine, vitamin C, vitamin B 12, amoxicillin and other 1 1 API products have obtained EU COS certification. 20 10 in may, the oral solid preparation workshop, vitamin c and sodium vitamin c of the group passed the FDA certification of the world's highest drug quality standard with "zero defect". It is the first pharmaceutical manufacturer in China that has passed the FDA certification by using domestic equipment, and the first enterprise in Asia that has passed the FDA certification for online production, and has obtained the "passport" to enter the high-end pharmaceutical market in Europe and America.
In terms of brand building, Unacon owns four well-known trademarks in China: Shi Yao, Ou Yi, Guoweikang and Enbipu. According to the evaluation of World Brand Lab, one of the top five brand value evaluation agencies in the world, Shi Yao brand has been selected as "China 500 Most Valuable Brands" for four consecutive times since 2005. Unacon has been selected as one of the top 500 Chinese enterprises for three times in a row, and was shortlisted for the 2009 China Most Brand Value Enterprise Award.
In fulfilling social responsibilities, Unakang has always taken the lead and always enthusiastically supported social welfare undertakings. Stone medicine is always indispensable in SARS, Indonesian tsunami, Wenchuan earthquake, Yushu earthquake, medical care for seriously ill children, voluntary service, condolences to the old areas and other activities. Unacon keeps giving back to the society with tangible things. Since the establishment of the enterprise, * * * has invested more than 60 million yuan in public welfare undertakings.